Oral vs Intravenous Dexamethasone in Total Knee Arthroplasty

This prospective observational cohort study aims to evaluate the association between perioperative dexamethasone administration and early postoperative recovery following primary total knee arthroplasty. In routine clinical practice, dexamethasone may be administered orally, intravenously, or not administered, depending on the surgeon's established perioperative protocol. The primary objective is to assess early postoperative recovery in terms of pain intensity, functional mobility, and knee joint range of motion. Secondary objectives include evaluation of inflammatory response, postoperative metabolic changes, opioid requirement, and the severity of postoperative nausea and vomiting (PONV). Group allocation is non-randomized and determined solely by the standard perioperative management approach routinely applied by the surgeon selected by the patient. No additional interventions are introduced for research purposes. All outcomes are assessed prospectively during the early postoperative period.

NCT Number	NCT07442812
Lead Sponsor	Haseki Training and Research Hospital
Conditions	Knee Osteoarthritis, Gonarthrosis; Primary, Total Knee Arthroplasty
Enrollment	270 participants
Start Date	2026-03-31
Primary Completion	2026-12 (estimated)
Study Completion	2027-10 (estimated)
Updated on ClinicalTrials.gov	2026-05-20